{"id":"W2793257861","doi":"10.1002/cpdd.439","title":"Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Tolerability; Pharmacokinetics; Nonsteroidal; Atopic dermatitis; Incidence (geometry); Cohort; Adverse effect; Safety profile; Open label; Pharmacology; Dermatology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002315795,0.001193772,0.00178285,0.0002369739,0.000501314,0.0007438252,0.0005541684,0.0009514104,0.0029947],"category_scores_gemma":[0.001659182,0.0005184287,0.001033635,0.0002347022,0.0006080261,0.0009772163,0.0002055602,0.00207774,0.0006906297],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005059036,"about_ca_system_score_gemma":0.001045902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005879407,"about_ca_topic_score_gemma":0.001003043,"domain_scores_codex":[0.9992945,0.0003126801,0.00003995064,0.0001319401,0.0001176448,0.0001032791],"domain_scores_gemma":[0.9987137,0.0003098653,0.0002996342,0.0001589862,0.0001891527,0.0003286372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4230447,0.1326272,0.0192142,0.001197832,0.001824913,0.0006446092,0.0006364679,0.002487312,0.3030241,0.000200919,0.004926592,0.1101713],"study_design_scores_gemma":[0.08146857,0.8403945,0.04896098,0.00003283103,0.0009897861,0.0007183795,0.0001420527,0.001359952,0.02277028,0.0001762097,0.002925728,0.00006063232],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995137,0.0009341231,0.0009118801,0.0001265279,0.00003359928,0.001151592,0.0009865009,0.00006227615,0.0006564397],"genre_scores_gemma":[0.9935154,0.0008415317,0.001527089,0.0003904077,0.0001086846,0.0008766641,0.001534406,0.00003914913,0.001166673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0029947,"threshold_uncertainty_score":0.0122472,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0443249687538772,"score_gpt":0.4239657936168991,"score_spread":0.3796408248630219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}